Suppr超能文献

他汀类药物在心力衰竭的预防和治疗中的作用:证据回顾。

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence.

机构信息

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland.

出版信息

Curr Atheroscler Rep. 2019 Jul 27;21(10):41. doi: 10.1007/s11883-019-0800-z.

Abstract

PURPOSE OF REVIEW

We summarize the best evidence for statins in the prevention and treatment of heart failure.

RECENT FINDINGS

In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without heart failure), statins reduce the risk of incident heart failure-mainly by preventing myocardial infarction although an additional benefit from reducing myocardial ischemia cannot be excluded. However, in patients with established heart failure, statins do not reduce the risk of cardiovascular death, which is mainly caused by pump failure and ventricular arrhythmias. Retrospective analyses, however, suggest that statins may reduce the rate of heart failure hospitalization and atherosclerotic events (which are proportionately much less common in these patients than heart failure hospitalization or death). Statin therapy should probably be continued in patients with coronary artery disease developing heart failure, although the weak evidence and small benefit may not justify the use of this treatment in very elderly patients with a short life expectancy and in which polypharmacy is a problem.

摘要

目的综述

我们总结了他汀类药物在心力衰竭预防和治疗中的最佳证据。

最新发现

对于存在心血管危险因素或已确诊动脉粥样硬化性心血管疾病(但无心力衰竭)的患者,他汀类药物可降低心力衰竭的发生风险,主要是通过预防心肌梗死实现的,尽管降低心肌缺血的获益不能排除。然而,对于已确诊心力衰竭的患者,他汀类药物并不能降低心血管死亡风险,这主要是由泵衰竭和室性心律失常导致的。然而,回顾性分析表明,他汀类药物可能会降低心力衰竭住院率和动脉粥样硬化事件的发生率(与心力衰竭住院或死亡相比,这些患者发生这些事件的比例要低得多)。对于发生心力衰竭的冠状动脉疾病患者,可能需要继续他汀类药物治疗,尽管证据较弱,获益较小,可能无法证明在预期寿命较短且存在多药治疗问题的非常高龄患者中使用该治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验